Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology  |  Pediatrics/Neonatology

Search Medical Condition
Please enter condition
Please choose location

Leukemia (Pediatric) Clinical Trials

A listing of Leukemia (Pediatric) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (88) clinical trials

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01190930?term=AALL0932&rank=1

Phase N/A

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01307579?term=Children%27s+Oncology+Group&cond=Prevent+Invasive+Fungal+Infection+in+Children+Undergoing+Chemotherapy+for+Acute+Myeloid+Leukemia+%28AML%29&rank=1

Phase N/A

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT00408005?term=AALL0434&rank=2

Phase N/A

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01142427?term=AALL08B1&rank=1

Phase N/A

Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment

To assess the impact of moderate hepatic impairment on cytarabine and daunorubicin pharmacokinetics and their metabolites following administration of CPX-351.

Phase

Study of Palbociclib in MLL-rearranged Acute Leukemias

Diagnosis: Acute myeloid leukemia; Acute lymphoblastic leukemia Age ≥ 18 years, no upper age limit Study drug: Palbociclib Phase Ib/IIa, open-label - Phase Ib: Based on previous experience with 125 mg palbociclib once daily for 21 days followed by 7 days of rest in patients with breast cancer, liposarcoma, non-small ...

Phase

Study to Evaluate the Safety Tolerability and Pharmacokinetics of DS-3032b in Hematological Malignancies

This will be a Phase 1, open-label study of DS-3032b to assess its safety and tolerability and identify a Maximum Tolerated Dose (MTD)/tentative Recommended Phase II Dose (RP2D) in subjects with refractory or relapsed Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia (CML) in blast phase, or ...

Phase

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Pegylated (PEG) L-Asparaginase

The purpose of this study is to compare the effect of a blood thinning drug called Apixaban versus no administration of a blood thinning drug, in preventing blood clots in children with leukemia or lymphoma. Patients must be receiving chemotherapy; including Pegylated L-Asparaginase and have a central line (a catheter ...

Phase